Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “THB335 is an orally administered capsule added to a stable background regimen of a second generation H1 antihistamine.”In the company’s words, NCT07766499 on ClinicalTrials.gov
- Main trialPhase 2
- “THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment. The study includes a Screening Period of up to 4 weeks, a 12-week Treatment Period, and a 4-week Follow-Up Period, for a total participant duration of approximately 20 weeks.”In the company’s words, NCT07766499 on ClinicalTrials.gov
Other drugs for Chronic Spontaneous Urticaria (CSU)
- RemibrutinibNovartis · Phase 3
- MG-K10Shanghai Mabgeek Biotech.Co.Ltd · Phase 3
- JYB1904Jemincare · Phase 3
- TLL-018Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 3
- LP-003Longbio Pharma · Phase 3
- BarzolvolimabCelldex Therapeutics · Phase 3
Coming up1
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2027 | A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026